Recombinant Erythropoietin: Payment Options for Medicare

Description:

Policy interest in Medicare’s payment policies regarding recombinant erythropoietin has arisen chiefly because of the biologic’s expense. Because of concern about the implications of recombinant erythropoietin use for Medicare expenditures, the House Ways and Means Committee, Subcommittee on Health, requested OTA to examine alternative payment policies that Medicare might adopt to pay for the biologic. In responding to that request, this Special Report reviews clinical and economic issues regarding the use of recombinant erythropoietin and develops a series of options for Congressional consideration.

Creator(s): United States. Congress. Office of Technology Assessment.
Location(s): United States
Creation Date: May 1990
Partner(s):
UNT Libraries Government Documents Department
Collection(s):
Office of Technology Assessment
Usage:
Total Uses: 80
Past 30 days: 2
Yesterday: 0
Creator (Author):
Publisher Info:
Date(s):
  • Creation: May 1990
Coverage:
Place
United States
Description:

Policy interest in Medicare’s payment policies regarding recombinant erythropoietin has arisen chiefly because of the biologic’s expense. Because of concern about the implications of recombinant erythropoietin use for Medicare expenditures, the House Ways and Means Committee, Subcommittee on Health, requested OTA to examine alternative payment policies that Medicare might adopt to pay for the biologic. In responding to that request, this Special Report reviews clinical and economic issues regarding the use of recombinant erythropoietin and develops a series of options for Congressional consideration.

Physical Description:

108 p. : ill. ; 28 cm.

Language(s):
Subject(s):
Series Title: Special Report
Partner:
UNT Libraries Government Documents Department
Collection:
Office of Technology Assessment
Identifier:
  • LOCAL-CONT-NO: 9038
  • SUDOC: Y 3.T 22/2:2 R 24
  • UNTCAT: b1605453 |
  • ARK: ark:/67531/metadc39668
Resource Type: Report
Format: Text